title: Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats.
abstract: BACKGROUND
  Although patients with heart failure express elevated circulating levels of tumor necrosis factor-alpha (TNF-alpha) in their peripheral circulation, the structural and functional effects of circulating levels of pathophysiologically relevant concentrations of TNF-alpha on the heart are not known.
  
  
  RESULTS
  Osmotic infusion pumps containing either diluent or TNF-alpha were implanted into the peritoneal cavity of rats. The rate of TNF-alpha infusion was titrated to obtain systemic levels of biologically active TNF-alpha comparable to those reported in patients with heart failure (approximately 80 to 100 U/mL), and the animals were examined serially for 15 days. Two-dimensional echocardiography was used to assess changes in left ventricular (LV) structure (remodeling) and LV function. Video edge detection was used to assess isolated cell mechanics, and standard histological techniques were used to assess changes in the volume composition of LV cardiac myocytes and the extracellular matrix. The reversibility of cytokine-induced effects was determined either by removal of the osmotic infusion pumps on day 15 or by treatment of the animals with a soluble TNF-alpha antagonist (TNFR:Fc). The results of this study show that a continuous infusion of TNF-alpha led to a time-dependent depression in LV function, cardiac myocyte shortening, and LV dilation that were at least partially reversible by removal of the osmotic infusion pumps or treatment of the animals with TNFR:Fc.
  
  
  CONCLUSIONS
  These studies suggest that pathophysiologically relevant concentrations of TNF-alpha are sufficient to mimic certain aspects of the phenotype observed in experimental and clinical models of heart failure.
authors.affiliation: Department of Medicine, Veterans Administration Medical Center, Baylor College of Medicine, Houston, Tex 77030, USA.
authors.forename: B
authors.initials: B
authors.lastname: Bozkurt
authors.forename: S B
authors.initials: SB
authors.lastname: Kribbs
authors.forename: F J
authors.initials: FJ
authors.lastname: Clubb
authors.forename: L H
authors.initials: LH
authors.lastname: Michael
authors.forename: V V
authors.initials: VV
authors.lastname: Didenko
authors.forename: P J
authors.initials: PJ
authors.lastname: Hornsby
authors.forename: Y
authors.initials: Y
authors.lastname: Seta
authors.forename: H
authors.initials: H
authors.lastname: Oral
authors.forename: F G
authors.initials: FG
authors.lastname: Spinale
authors.forename: D L
authors.initials: DL
authors.lastname: Mann
mesh_terms: D000818:Animals; D002303:Cardiac Output, Low / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology*; D004249:DNA Damage; D019281:Dimerization; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D006321:Heart / Q000187:drug effects; D006439:Hemodynamics / Q000502:physiology; D015918:Infusion Pumps, Implantable; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology*; D014463:Ultrasonography; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology*
chemical_list: D014409:Tumor Necrosis Factor-alpha